Literature DB >> 35076853

Curcumin sensitizes carboplatin treatment in triple negative breast cancer through reactive oxygen species induced DNA repair pathway.

Genjin Wang1, Peng Duan2, Zhengkuo Wei3, Feng Liu3.   

Abstract

BACKGROUND: As patients with triple-negative breast cancer (TNBC) have a very weak response to hormone inhibition or anti-HER2 therapy, traditional chemotherapy is commonly used in these patients. Recently, carboplatin has been approved for the clinical treatment of TNBC. However, several patients exhibit resistance to carboplatin treatment. Therefore, strategies to enhance the antitumor effect of carboplatin need to be explored. In our study, we investigated the function of curcumin in increasing the response to carboplatin. METHODS AND
RESULTS: MTT and colony formation assays were used to evaluate cell viability after carboplatin and curcumin treatment. In addition, we conducted flow cytometric and Western blot analyses to examine cellular apoptosis. Subsequently, molecular and biochemical experiments were used to explore the mechanism by which curcumin sensitized TNBC to carboplatin treatment. We demonstrated that different TNBC cells responded differently to carboplatin. Low-dose carboplatin killed CAL-51 cells but barely influenced CAL-51-R and MDA-MB-231 cells. To improve the sensitivity of resistant TNBC cells to carboplatin, combined treatment with curcumin was applied and was found to inhibit proliferation and induce apoptosis. Mechanistically, curcumin exerted its anticancer effect by increasing reactive oxygen species (ROS) production, which downregulated the DNA repair protein RAD51, leading to upregulation of γH2AX. As expected, ROS scavenger NAC reversed the inhibitory effect on growth and DNA repair pathway activity mediated by curcumin.
CONCLUSION: Collectively, our data demonstrate that curcumin sensitizes TNBC to the anticancer effect of carboplatin by increasing ROS-induced DNA damage, thus providing an effective combination treatment strategy for TNBC.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Carboplatin; Curcumin; DNA repair; ROS; Triple negative breast cancer (TNBC)

Mesh:

Substances:

Year:  2022        PMID: 35076853     DOI: 10.1007/s11033-022-07162-1

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  35 in total

1.  Carboplatin-based combination chemotherapy for elderly patients with advanced bladder cancer.

Authors:  Takahiro Yoneyama; Yuki Tobisawa; Tohru Yoneyama; Hayato Yamamoto; Atsushi Imai; Shingo Hatakeyama; Yasuhiro Hashimoto; Takuya Koie; Chikara Ohyama
Journal:  Int J Clin Oncol       Date:  2014-05-29       Impact factor: 3.402

2.  Cancer Statistics, 2021.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2021-01-12       Impact factor: 508.702

3.  Combination therapy with carboplatin and paclitaxel for small cell lung cancer.

Authors:  Atsuto Mouri; Ou Yamaguchi; Sachiko Miyauchi; Ayako Shiono; Harue Utsugi; Fuyumi Nishihara; Yoshitake Murayama; Hiroshi Kagamu; Kunihiko Kobayashi
Journal:  Respir Investig       Date:  2018-10-24

Review 4.  Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.

Authors:  Carsten Denkert; Cornelia Liedtke; Andrew Tutt; Gunter von Minckwitz
Journal:  Lancet       Date:  2016-12-07       Impact factor: 79.321

Review 5.  Triple-negative breast cancer--current status and future directions.

Authors:  O Gluz; C Liedtke; N Gottschalk; L Pusztai; U Nitz; N Harbeck
Journal:  Ann Oncol       Date:  2009-11-09       Impact factor: 32.976

6.  Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer.

Authors:  Madoka Iwase; Masashi Ando; Kenjiro Aogi; Tomoyuki Aruga; Kenichiro Inoue; Akihiko Shimomura; Eriko Tokunaga; Norikazu Masuda; Hideko Yamauchi; Toshinari Yamashita; Hiroji Iwata
Journal:  Breast Cancer Res Treat       Date:  2020-03-05       Impact factor: 4.872

Review 7.  Metastatic and triple-negative breast cancer: challenges and treatment options.

Authors:  Sumayah Al-Mahmood; Justin Sapiezynski; Olga B Garbuzenko; Tamara Minko
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

8.  The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers.

Authors:  Daniela Annibali; Anna A Sablina; Frédéric Amant; Stijn Moens; Peihua Zhao; Maria Francesca Baietti; Oliviero Marinelli; Delphi Van Haver; Francis Impens; Giuseppe Floris; Elisabetta Marangoni; Patrick Neven
Journal:  Sci Rep       Date:  2021-02-04       Impact factor: 4.379

Review 9.  Triple-negative breast cancer molecular subtyping and treatment progress.

Authors:  Li Yin; Jiang-Jie Duan; Xiu-Wu Bian; Shi-Cang Yu
Journal:  Breast Cancer Res       Date:  2020-06-09       Impact factor: 6.466

Review 10.  Molecular subtypes and precision treatment of triple-negative breast cancer.

Authors:  Shen Zhao; Wen-Jia Zuo; Zhi-Ming Shao; Yi-Zhou Jiang
Journal:  Ann Transl Med       Date:  2020-04
View more
  3 in total

Review 1.  Smart Nanoparticles for Breast Cancer Treatment Based on the Tumor Microenvironment.

Authors:  Xiao Luo; Qi Zhang; Hongbo Chen; Kai Hou; Ning Zeng; Yiping Wu
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

Review 2.  Effects and Mechanisms of Curcumin for the Prevention and Management of Cancers: An Updated Review.

Authors:  Zhi-Jun Yang; Si-Yu Huang; Dan-Dan Zhou; Ruo-Gu Xiong; Cai-Ning Zhao; Ai-Ping Fang; Yun-Jian Zhang; Hua-Bin Li; Hui-Lian Zhu
Journal:  Antioxidants (Basel)       Date:  2022-07-28

Review 3.  The Synergistic Effects of Curcumin and Chemotherapeutic Drugs in Inhibiting Metastatic, Invasive and Proliferative Pathways.

Authors:  Maria Younes; Rita Mardirossian; Liza Rizk; Tia Fazlian; Jean Paul Khairallah; Christopher Sleiman; Hassan Y Naim; Sandra Rizk
Journal:  Plants (Basel)       Date:  2022-08-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.